DRKS00003881已完成3 期
A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer - VENICE
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 1,224
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- Male
入选标准
- •Histologically- or cytologically-confirmed prostate adenocarcinoma;
- •- Metastatic disease;
- •- Progressive disease while receiving hormonal therapy or after surgical castration;
- •- Effective castration.
排除标准
- •- Prior cytotoxic chemotherapy for prostate cancer, except estramustine and except
- •adjuvant/neoadjuvant treatment completed >3 years ago;
- •- Prior treatment with Vascular Endothelial Growth Factor (VEGF) inhibitors or VEGF
- •receptor inhibitors;
- •- Eastern Cooperative Oncology Group (ECOG) performance status >2.
- •The above information is not intended to contain all considerations relevant to a
- •patient's potential participation in a clinical trial.
研究者
相似试验
进行中（未招募）
不适用
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney DiseaseEUCTR2006-003173-27-PLAmgen Ltd334
进行中（未招募）
不适用
A Multicenter, Randomized, Double-blind Study Comparing De Novo OnceMonthly and Once Every 2 Week Darbepoetin alfa Dosing for the Correction ofAnemia in Subjects With Chronic Kidney Disease Not Receiving DialysisEUCTR2006-003173-27-GRAmgen Ltd540
进行中（未招募）
1 期
A Multicenter, Randomized, Double-blind Study Comparing De Novo Once Monthly and Once Every 2 Week Darbepoetin alfa Dosing for the Correction of Anemia in Subjects With Chronic Kidney Disease Not Receiving DialysisAnemia in subjects with chronic kidney disease not receiving dialysisMedDRA version: 9.1 Level: LLT Classification code 10002272 Term: AnemiaMedDRA version: 9.1 Level: LLT Classification code 10064848 Term: Chronic kidney diseaseEUCTR2006-003173-27-GBAmgen Ltd540
进行中（未招募）
不适用
A Multicenter, Randomized, Double-blind Study Comparing De Novo OnceMonthly and Once Every 2 Week Darbepoetin alfa Dosing for the Correction ofAnemia in Subjects With Chronic Kidney Disease Not Receiving DialysisAnemia in subjects with chronic kidney disease not receiving dialysisMedDRA version: 9.1Level: LLTClassification code 10002272Term: AnemiaMedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseEUCTR2006-003173-27-SIAmgen Ltd540
进行中（未招募）
不适用
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney DiseaseAnemia in subjects with chronic kidney disease not receiving dialysisMedDRA version: 14.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: LLTClassification code 10002272Term: AnemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2006-003173-27-DEAmgen Ltd334